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Objective: Engineered overexpression of tissue plasminogen activator (tPA) in vascular cells has been proposed as a means
to decrease intravascular thrombosis; however, tPA gene transfer has augmented intimal hyperplasia in vivo in some
studies. The purpose of this study was to define in vitro the effect of tPA gene transfer on smooth muscle cells (SMCs).
Methods: Human SMCs were retrovirally transduced with the tPA gene (SMCs/tPA).
Results: In the absence of plasminogen, no statistical differences in proliferation, migration, and morphology were
observed between SMCs/tPA and SMCs. In the presence of plasminogen, many differences became apparent. Matrix
metalloproteinase-2 (MMP-2) activation was 10-fold higher in SMCs/tPA than in SMCs. This activation was inhibited
by aprotinin, a plasmin inhibitor. Collagen degradation increased sevenfold in SMCs/tPA. SMCs/tPA contracted
dramatically in the presence of plasminogen. This cell contraction, indicative of extracellular matrix degradation, was
blocked by aprotinin and partially inhibited by MMP inhibitors. SMC/tPA-conditioned medium induced significantly
more SMC proliferation. The migration of SMCs/tPA through a porous membrane significantly exceeded untransduced
SMCs.
Conclusions: Over-expression of tPA in SMCs results in increased extracellular matrix degradation and can promote cell
proliferation and migration. This effect is mediated via plasmin, which further activates MMP-2. (J Vasc Surg 2005;42:
532-8.)
Clinical Relevance: TPA has been clinically used as a thrombolytic agent in the treatment of acute thrombotic disorders.
Transferring the tPA gene into vascular cells as a strategy of gene therapy has been proposed to enhance fibrinolytic
capability and therefore inhibit thrombosis and restenosis after vascular interventions. The mechanism(s) by which tPA
affects SMC proliferation and vascular remodeling has not been thoroughly characterized. This study unveils the
relationship between thrombolytic activity and intimal hyperplasia by showing how the elevated expression of tPA affects
the vascular remodeling. This study underscores that the overexpression of an enzyme thought beneficial to blood flow
can potentially compromise blood flow by altering the biology of the cell engineered to express it. The results are
important to the rational engineering of bioactive grafts with better patency. A new strategy to enhance the thrombolytic
ability of a vascular surface without inducing excessive neointimal hyperplasia is proposed.Tissue plasminogen activator (tPA) is a serine protease
that converts plasminogen into active plasmin, which then
degrades fibrin complexes, a major component of throm-
bus.1 tPA has been clinically used as a thrombolytic agent in
the treatment of acute thrombotic disorders.2
Transferring tPA into vascular cells has been proposed
as a means to enhance fibrinolytic capability and therefore
inhibit thrombosis and restenosis after vascular interven-
tions. The effect of tPA on restenosis is speculated, as tPA
can indirectly prevent intimal hyperplasia by reducing plate-
let aggregation on the luminal surface because of local
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532destabilization of fibrin cross-linkage. Furthermore, a lumi-
nal surface clot may stimulate a local inflammatory response
that could contribute to progressive atherosclerosis. Thus,
inhibition of the fibrin cross-linked stabilization of platelet
aggregates by in situ overexpression of tPA may have the
benefit of slowing the development of the lesions and
improving graft patency.
Overexpression of tPA in vascular endothelial cells and
smooth muscle cells (SMCs) has been achieved by viral
transfer of the tPA gene.3-5 Adenoviral-mediated tPA
gene transfer has been reported to prevent arterial
thrombus formation and to promote vessel patency in a
rabbit model.6 However, a thicker neointima has been
observed after tPA gene transfer in the injured artery of a
rabbit.7 Re-endothelialization with endothelial progenitor
cells that had been transduced with the tPA gene aggra-
vated intimal hyperplasia.8 We have also found that tPA
expression from seeded SMCs on a polytetrafluoroethylene
(PTFE) graft resulted in significantly thicker neointima on
PTFE grafts in a rabbit model,9 although this effect was not
observed in a long-term dog model with stent grafts.10
The mechanism(s) by which tPA affects SMC prolifer-
ation and vascular remodeling has not been thoroughly
characterized. tPA has been reported to play either no role
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out studies have shown that urokinase-type plasminogen
activator (uPA) exerts pro-neointimal effects.11-13 Both
tPA and uPA activate plasmin, which further activates elas-
tase and matrix metalloproteinases (MMPs). MMPs are a
family of proteolytic enzymes that degrade many compo-
nents of the extracellular matrix (ECM).14
To unveil the relationship between thrombolytic activ-
ity and intimal hyperplasia, we used an in vitro system to
evaluate the impact of tPA overexpression on SMC prolif-
eration andmigration.We found that increased tPA expres-
sion in SMCs affect the cellular behaviors mediated via
plasmin.
METHODS
Detailed Materials and Methods are provided in the
Online Data Supplement (online only).
SMC isolation and transduction. The protocol for
using human vein was approved by the Institutional Review
Board. Human SMCs were isolated from excreta human
saphenous veins by collagenase digestion and cultured in
Williams’ medium (GIBCO BRL, Gaithersburg, Md) con-
taining 20% fetal bovine serum (FBS), L-glutamine (2
mM), and antibiotics, as described previously.5
SMCs were transduced with murine leukemia virus-
derived viral vectors (G1nBgSvNa and G1wTSvNa)15-16 to
generate SMC/lacZ and SMC/tPA populations after
G418 (GIBCO BRL) selection. The production of tPA
from SMCs/tPA was 1.6 IU and 10 ng/105 cells in 24
hours for enzyme activity and antigen concentration, re-
spectively, while the production of tPA from SMCs and
SMCs/lacZ was at undetectable level.
Cell proliferation assay. SMCs, SMCs/lacZ, and
SMCs/tPA (2  104 cells/well in a 24-well plate) were
cultured with serum-free Williams’ medium in the presence
or absence of plasminogen (10 g/mL) for 24 hours, at
which time 2% FBS was added to the medium, and the cells
were cultured for another 48 hours. Then the cells were
pulse-labeled with [3H]thymidine (1 Ci/well) for 6
hours. The incorporated 3[H]thymidine was measured in a
scintillation counter and expressed as count per minute per
cell.
To measure cell proliferation in conditioned media,
confluent SMCs and SMCs/tPA were cultured for 48
hours with serum-free media, without or with plasmino-
gen. The supernatants were collected to culture SMCs (1
104 cell/well in a 24-well plate) that were quiescent after
being precultured in serum-free medium for 48 hours.
After 24 and 48 hours, the cells in the wells were counted.
Cell morphology assay. After being cultured to 100%
confluence in serum-containing medium, SMCs, SMCs/
lacZ, and SMCs/tPA were cultured for 48 hours with
serum-free Williams’ medium, either with or without plas-
minogen. The cells were then fixed, stained, and photo-
graphed.
In the inhibition of cell contraction assay, the serum-
free media in the SMC/tPA culture contained the follow-
ing inhibitors: (1) no inhibitor (control), (2) aprotinin, (3)MMP-2 inhibitor (Calbiochem, San Diego, Calif), (4)
MMP inhibitor II, (5) MMP inhibitor III, and (6) MMP
inhibitor IV. The percent inhibition was calculated by
measuring the surface area coverage of cells and consider-
ing that aprotinin has 100% inhibition.
Cell migration assay. SMCs or SMCs/tPA were
plated on top of the Costar (Corning, NY) transwell filter
inserts inside a 24-well plate. After being cultured in serum-
free medium, either with or without plasminogen for 48
hours, 5% FBS was added to the medium in the lower
chamber, followed by overnight incubation. The total and
migrated cells were counted separately to calculate the
migration rate.
Collagen degradation assay. Cells were mixed with
fluorescein isothiocyanate (FITC)-labeled (1 mg/mL) and
unlabeled (5 mg/mL) bovine collagen type I at 106
cells/mL and plated (325 L/well) in a 12-well plate.
Phenol-red-free media 199 were used to culture the cells in
the presence or absence of plasminogen. Collagen degra-
dation and release were represented by the fluorescence in
the conditioned medium at various times of culture.
The collagen concentration in the supernatant of cell
culture was analyzed with enzyme-linked immunosorbent
assay (ELISA)17 after SMCs/tPA were cultured with serum-
free medium, with or without plasminogen, for 48 hours.
MMP activity assays. The same conditioned media
mentioned in collagen assay section was analyzed with
gelatin zymography for MMP-2 and MMP-9 activity.18
The ratio of active MMP-2 over total MMP-2 was calcu-
lated after the density of the bands was measured.
Gene expression measurements. Real-time polymer-
ase chain reaction (PCR) amplification and quantification
of target RNAs isolated from cells was performed using the
TaqMan reverse transcriptase PCR (RT-PCR) kit (Applied
Biosystems, Foster City, Calif). The results were normal-
ized to the ribosomal 18s RNA signal. Expression of
MMP-2 and PAI-1 genes was analyzed by semi-quantitative
RT-PCR of the isolated total RNA,19 which was normalized
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA.
Protein array. Human Angiogenesis Antibody Array
1 (RayBiotech, Inc, Norcross, Ga) was used to measure
proteins in the serum-free medium cultured with SMC/
tPA in the presence or absence of plasminogen for 48
hours.
Statistical analysis. Experimental values were ex-
pressed as mean  standard deviation. Statistically signifi-
cant differences among the groups were compared by using
one-way analysis of variance (ANOVA) for multiple groups
or the two-tailed Student’s t-test for two groups only.
Significance was attributed to a value of P  .05.
RESULTS
Cell proliferation. Cell proliferation was measured by
using a radioactive-labeled thymidine incorporation assay
(Fig 1, A) and direct cell number count (data not shown).
No significant differences among SMCs, SMCs/lacZ, and
SMCs/tPA were detected by either assay when the cells
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in serum-freemedium, either in the presence or the absence
of plasminogen.
To further study the mitogenic effect of tPA gene
transfer, the SMC- or SMC/tPA-conditioned media were
collected to culture fresh SMCs. SMCs proliferated signifi-
cantly faster (P  .01, n  3) in the SMC/tPA-conditioned
medium with plasminogen than without plasminogen, but
no difference was observed with SMC-conditioned me-
dium (Fig 1, B). These data suggest that mitogens are
released from SMCs/tPA in the presence of plasminogen.
Cell morphology. No difference in morphology was
observed between SMCs, SMCs/lacZ, and SMCs/tPA
under normal culture conditions with serum-containing
medium (Fig 2 a, b, and c). However, SMCs/tPA had a
Fig 1. Cell proliferation. A, DNA synthesis assay. SMCs (black),
SMCs/lacZ (grey), and SMCs/tPA (white) were cultured in the
medium with 2% fetal bovine serum after being treated for 24
hours in serum-free medium, either in the presence or the absence
of plasminogen. The cells were pulse labeled with 3[H]thymidine
for 6 hours. The incorporated 3[H]thymidine was expressed as
count per minute (cpm) per cell. B, Cell proliferation in condi-
tioned media. Confluent cells were cultured for 48 hours with
serum-free media either without plasminogen (SMCs, white;
SMCs/tPA, hatched) or with plasminogen (SMCs, diamonds;
SMCs/tPA, black). These supernatants were used to culture SMCs
on a 24-well plate. After being cultured for 24 and 48 hours, the
cell numbers in the wells were counted. Cell proliferation was
expressed as cell number increase compared with that at time  0
(1  104 cell/well). *P  .01 compared with others (one-way
analysis of variance). Similar results as SMCs were obtained for
SMCs/lacZ (data not shown). SMCs, Smooth muscle cells; tPA,
tissue plasminogen activator.significantly decreased surface area after culture in serum-free medium with plasminogen for 48 hours (Fig 2, f), but
the morphology of control SMCs and SMCs/lacZ did not
change at the same condition (Fig 2, d and e). The cell
number remained constant after being cultured with plas-
minogen (SMCs/tPAwith plasminogen, 8.0 0.65 104
vs without plasminogen, 7.2 0.6 104; P .18, n 3),
indicating the shrinking phenomena was not due to cell
loss. Staining with 4’, 6-diamidino-2-phenylindole (DAPI)
was performed to examine the apoptotic cells. The number
of apoptosis cell in shrinking SMCs/tPA (10% 2%) is not
significantly different from that of SMCs (11%  1%) and
SMCs/lacZ (11%  3%, P  .5).
To determine whether the cell shrinkage was a result of
tPA-plasmin–induced ECM degradation, inhibitors of
plasmin and MMP were added into the culture media. The
cell shrinkage was inhibited by the plasmin inhibitor, apro-
tinin (Fig 3, A-b), implicating the involvement of plasmin
in the cell shrinkage. Specific inhibition of MMP-2 inhib-
ited approximately only 18% cell shrinkage (Fig 3, A-c).
Nonspecific inhibitors of MMP II (Fig 3, A-d) or III (Fig 3,
A-e) or IV (Fig 3, A-f) resulted in more blockage of cell
shrinkage. The inhibition effect increased along with the
broader MMP inhibition spectrum. MMP inhibitor IV,
which inhibits a broader spectrum of MMPs, inhibits cell
shrinkage by 62% compared with the 100% inhibition ef-
fectiveness achieved by aprotinin (Fig 3, B). In the absence
of plasminogen, the inhibitors had no effect on cell mor-
phology (data not shown). These results suggest that vari-
ous MMPs may participate in the process of cell shrinkage.
SMC migration. SMC mobility was analyzed with a
modified Boyden chamber assay. The percentage of
SMCs/tPA migrating through a porous membrane in the
presence of plasminogen significantly exceeded that in the
absence of plasminogen (62% 3% vs 43% 1%; P .02,
n 9). Untransduced SMC migration was independent of
plasminogen; its migration percentage (45% to 50%) was
similar to SMCs/tPA in the absence of plasminogen (Fig
4). Treatment with aprotinin or MMP inhibitor IV blocked
the enhanced migration (Fig E2, online only). The results
suggest that plasmin and MMPs participate in the tPA-
induced cell migration.
Collagen degradation. To examine tPA-induced
ECM degradation, type I and IV collagens in the culture
supernatant of SMCs/tPA were measured by ELISA. Colla-
genswere detected in SMC/tPA supernatantswhen cellswere
cultured in the absence of plasminogen (0.12 0.01g/mL
type I collagen and0.080.01g/mL type IV collagen) but
not when plasminogen was present (Fig 5, A). This demon-
strates that the collagens secreted from cells were degraded
through a pathway involving tPA and plasmin.
To confirm collagen degradation by the cultured cells,
SMCs and SMCs/tPAwere embeddedwithin a fluorescence-
conjugated type I collagen gel and cultured in the presence or
absence of plasminogen for 48 hours. Degradation of colla-
gen results in the release of fluorescence into the culture
supernatant. The SMC/tPA-embedded collagen gel re-
leased sevenfold more fluorescence in the presence of plas-
minogen than in the absence of plasminogen (Fig 5, B).
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gen gel was low and independent of the presence of plas-
minogen.
MMP-2 activation. The activities of MMP-2 and
MMP-9 from cultured SMCs and SMCs/tPA were studied
by using gelatin zymography (Fig 6). A strong pro-MMP-2
band, but faint pro-MMP-9 band, was detected in the
culture supernatants from both SMCs and SMCs/tPA. The
active MMP-2 band from both SMCs and SMCs/tPA was
faint in the absence of plasminogen (Fig 6, lanes 1 and 3).
The relative amount of activeMMP-2 from SMCs/tPAwas
increased 10-fold, from 0.4%  0.1% in the absence of
plasminogen (Fig 6, lane 3) to 4%  0.8% in the presence of
plasminogen (Fig 6, lane 4), whereas pro-MMP-2 from
SMC was not activated by addition of plasminogen (Fig 6,
lane 2). Aprotinin inhibited the activation of MMP-2 (Fig
6, lane 5), which suggests that plasmin activation is neces-
sary in vitro for MMP activation. More activated MMP-2
was also detected on the neointima formed on SMC/tPA-
seeded PTFE grafts implanted in rabbit aorta for 100 days
(Fig 6, lane 8) compared with those on grafts seeded with
no cells or with SMCs/lacZ (Fig 6, lanes 6 and 7). These
results support our hypothesis that tPA stimulates MMP
Fig 2. Effect of tPA/plasminogen on cell morphology.
i) were cultured in growth medium until confluent. Th
containing no plasminogen (upper panel) and plasmin
SMCs/tPA (10) shrinkage with no cell loss was observ
apoptotic cells (arrow points at white, condensed pyknot
and SMCs/LacZ (h). Scale bar  100 m. SMCs, Sm
4’,6-diamidino-2-phenylindole.activity by activating plasminogen both in vitro and in vivo.Effect of plasmin. Because plasmin is thought the
media causing the change in SMCs/tPA, plasmin (10 g/
mL) was directly added into the SMC culture. The addition
of plasmin to the SMC culture resulted in a phenomena
similar to that of SMCs/tPA in the presence of plasmino-
gen: cell shrinkage, MMP-2 activation, and more cell mi-
gration (data not shown). When tPA was directly added to
the SMC culture, no detectable change in immunostaining,
cell proliferation, morphology, or MMP-2 activity was
observed (data not shown).
Gene expression in SMC/tPA. Quantitative real-
time PCR and a semi-quantitative RT-PCR with RNA
isolated from SMCs and SMCs/tPA were performed to
evaluate gene expression. Expression of MMP-2 and PAI-1
genes was not significantly different between SMCs and
SMCs/tPA in the presence and absence of plasminogen
(Online Data Supplement). To examine the effect of tPA
expression from SMCs on other protein expression, an
antibody array was used to detect a set of angiogenesis-
related proteins. No significant difference in the expression
of these proteins was detected (Online Data Supplement).
DISCUSSION
Gene transfer of tPA is under investigation as a possible
s (a, d, g), SMCs/lacZ(b, e, h), and SMCs/tPA (c, f,
ere then cultured for 48 hours with serum-free media
(10 g/mL) (middle panel) and stained with H&E.
. DAPI staining (lower panel) shows a similar number of
clei) in shrunk SMCs/tPA (i) compared with SMCs (g)
muscle cells; tPA, tissue plasminogen activator; DAPI,SMC
ey w
ogen
ed (f)
ic nu
oothmeans to reduce thrombosis and restenosis.3-5 Such transfer
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tima formation in vivo, however.6-8 These issues must be
resolved before this type of approach can be validated for
Fig 3. Inhibition of smooth muscle cell/tissue plasminogen activa-
tor (SMC/tPA) shrinking. A, Confluent SMCs/tPA were cultured
for 48 hours with serum-free media containing plasminogen plus (a)
none, (b) aprotinin, (c)matrix metalloproteinase-2 (MMP-2) inhib-
itor, (d) MMP inhibitor II, (e) MMP inhibitor III, and (f) MMP
inhibitor IV.Cells were stainedwith 0.1% crystal violet.B,Assessment
of inhibitor effect. The area of cell coverage in panel A was measured
digitally. Inhibition of cell shrinking by aprotinin (b) is defined as
100%. Inhibition byMMP inhibitors was normalized to the aprotinin
effect. Each column represents 36data points from three experiments,
with triplicates at the specified condition. Each well was photo-
graphed at four microscopic views at 100 magnification for digital
analysis.
Fig 4. Migration of smooth muscle cells (SMCs). SMCs (white),
SMCs/LacZ (hatched), and SMCs/tissue plasminogen activator
(black)were subconfluently plated on top of the transwell filter inserts
inside a 24-well plate. After being cultured for 48 hours in serum-free
medium, with or without plasminogen, 5% fetal bovine serum was
added to the medium in the lower chamber. After overnight incuba-
tion, the total cells in the inserts and the cells that hadmigrated to the
lower surfacewere counted. Percentmigration is the ratio ofmigrated
cells to the total number of cells. Each column represents data from
three experiments, with triplicates at the specified condition. *P .01
compared with others (one-way analysis of variance).clinical use. In this study, we report the probable pathwaywhereby engineered expression of tPA in SMCs can induce
intimal hyperplasia.
There was no detectable difference between SMCs and
SMCs/tPA when the cells were cultured in the absence of
plasminogen, indicating that tPA itself does not alter SMC
properties. Similarly, the addition of plasminogen to un-
transduced SMCs did not affect SMC growth or morphol-
ogy. The differences between SMCs and SMCs/tPA were
observed only when plasminogen was added to the culture.
These results indicate that it is the activation of plasmino-
gen into plasmin by secreted tPA that dramatically alters the
characteristics and behavior of SMCs. Direct addition of
plasmin to the culture of SMCs reproduced the effect of
SMCs/tPA with plasminogen, confirming that the change
in SMCs/tPA is mediated via plasmin.
tPA-activated plasmin further cleaves pro-MMP-2 into
active MMP-2 (Fig 6). Other MMPs, including MMP-1,
MMP-3, and MMP-9, have also been reported to be acti-
vated by plasmin.20,21 Plasmin and MMPs are nonspecific
proteinases that can degrade ECM and basement mem-
brane molecules.22-24 We demonstrated that collagen, a
major ECM component, was degraded by SMC/tPA only
in the presence of plasminogen (Fig 5). This confirms that
Fig 5. Collagen degradation. A, Smooth muscle cells/tissue plas-
minogen activator (SMCs/tPA) were cultured in the absence (gray)
or presence (black) of plasminogen for 48 hours. Type I and IV
collagens in the supernatant were measured using an enzyme-linked
immunosorbent assay. Data were from two experiments of triplicate
assays. B, SMCs (white) and SMCs/tPA (black) were embedded
within fluorescein isothiocyanate-conjugated type I collagen gel and
cultured in the presence or absence of plasminogen for 48 hours.
Fluorescence in the conditioned medium was measured.the activation of plasmin and other possible proteinases
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that SMC/tPA degrades significantly more ECM in the
presence of plasminogen.
Degradation of the ECM by plasmin is the stimulus for
all of the other changes observed in SMCs/tPA, including
shrinkage, growth stimulation, and migration. The cell
shrinkage (Fig 2, f) could be explained by degradation of
ECM that is responsible for cell adhesion and spread.
Shrinkage of SMCs/tPA in the presence of plasminogen
was blocked by aprotinin and partially blocked by MMP
inhibitors, indicating that plasmin and activated MMPs
were responsible. When the activity of plasmin was inhib-
ited, activation of MMP was blocked, resulting in blockage
of ECM degradation. These results explain why cell shrink-
age was totally inhibited (Fig 3, A-b). The specific MMP-2
inhibitor had less effect (Fig 3, A-c), indicating MMP-2
may play a limited role in ECM degradation. The correla-
tion of the blockage with the activity of MMPs demon-
strates the involvement of various MMPs in the ECM
degradation (Fig 3, A-d to f). The data suggest that no
singleMMP alone seemed to result in the full cell-shrinkage
phenomena.
It was reported that tPA itself has a mitogenic effect.25
We did not, however, observe a similar effect of tPA in
SMCs on proliferation in the absence of plasminogen (Fig
1, A). SMC proliferation was only enhanced by condi-
tioned medium from SMC/tPA culture and only then in
the presence of plasminogen, indicating that mitogens are
released into the conditioned medium only under these
specific conditions. The mitogens released from ECM deg-
Fig 6. Effect of tissue plasminogen activator (tPA) on matrix
metalloproteinase-2 (MMP-2) activity. The zymography shows
the MMP-2 and MMP-9 activity in the conditioned medium
cultured with smooth muscle cells (SMCs) (lanes 1 and 2) and
SMCs/tPA (lanes 3 to 5). In the absence of plasminogen, no active
MMP-2 was detected either in SMCs (lane 1) or in SMCs/tPA
(lane 3). In the presence of plasminogen, an active MMP-2 band
was detected in SMCs/tPA (lane 4), but not in SMCs (lane 2).
Lane 5: same as lane 4 but with the addition of the plasmin
inhibitor aprotinin showing the faint active MMP-2 band. The
MMP-2 and MMP-9 activity in the neointima on the polytetra-
fluoroethylene grafts that were recovered 100 days after implanta-
tion in the rabbit abdominal aorta were similarly analyzed. Lane 6:
neointima on the graft seeded with no cells; lane 7: seeded with
SMCs/LacZ; and lane 8: seeded with SMCs/tPA. Lane M:MMP
markers.radation could be growth factors or ECM degradationproducts, including breakdown products of elastin 26 and
collagens.27 Growth factors such as platelet-derived growth
factor28 and fibroblast growth factor29 are normally seques-
tered within the ECM. Degradation of ECM releases these
growth factors into the medium.30
CONCLUSION
Our results provide an explanation for the in vivo
observations that tPA gene transfer can induce neointimal
hyperplasia in some models.7-9 Transduced SMCs secrete
tPA that activates plasminogen into plasmin. Plasmin fur-
ther activates pro-MMPs into active MMPs. Activation of
the nonspecific proteinases triggers a cascade of events,
starting with the degradation of ECM and leading to SMC
proliferation, morphology changes, and increased migra-
tion, each of which may promote intimal hyperplasia and
result in a thicker neointima.26,31,32
This study is the first to show how the elevated expres-
sion of tPA affects vascular remodeling, which is similar to
the role of urokinase-type plasminogen activator in pericel-
lular proteolysis during the process of cell migration, an-
giogenesis, healing, and tumor invasion.1 This study un-
derscores that overexpression of an enzyme thought
beneficial to blood flow can potentially compromise blood
flow by altering the biology of the cell engineered to
express it.
A new strategy to enhance the thrombolytic ability of a
vascular surface without inducing excessive neointimal hy-
perplasia could be to replace the wild-type tPA with a
zymogen tPA16,33 whose protease activity is not activated
until it binds to extracellular fibrin. This lower protease
activity would result in less ECM degradation and less
neointimal hyperplasia when tPA is used to develop a
thromboresistant graft.
We thank Kim Jaimes for technical support, Andrew
Huang for data collection, andDr KeithWebster for critical
reading of the manuscript.
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